The intestine and lungs perform different functions, but they are connected through the immune system, microbial metabolites and inflammatory signalling. This communication network is known as the gut–lung axis.

Research suggests that changes in the intestinal microbiome may influence immune activity in the respiratory tract. Lung infections and inflammation may also affect the intestinal environment. However, this does not mean that every respiratory problem begins in the gut or that a probiotic can prevent or treat every respiratory infection.

What Is the Gut Microbiome?

The gut microbiome is the community of bacteria, fungi, viruses and other microorganisms living in the gastrointestinal tract.

These organisms interact with digestion, metabolism, intestinal-barrier function and immune development. Their composition is influenced by factors such as:

• Diet and fibre intake
• Antibiotic exposure
• Gastrointestinal infections
• Age
• Sleep and stress
• Chronic illnesses
• Environment
• Other medicines

A balanced microbiome is not defined by one “good” organism. Different microorganisms interact with each other and with the individual’s immune system.

How Do the Gut and Lungs Communicate?

The gut–lung axis is bidirectional. Signals can travel from the intestine to the respiratory system and from the lungs back to the gut.

Microbial metabolites

Certain intestinal bacteria produce substances called short-chain fatty acids when they ferment dietary fibre. These metabolites can enter the circulation and influence immune-cell activity in other organs, including the lungs.

Immune signalling

A large part of the body’s immune system is associated with the intestinal tract. Immune cells activated in the gut may release chemical signals that influence inflammation and immune responses elsewhere.

Intestinal-barrier function

The intestinal lining helps control what passes from the gut into the bloodstream. Infection, inflammation, poor nutrition or other factors may disrupt this barrier and alter systemic immune signalling.

Effects of respiratory illness

Respiratory infections can affect appetite, diet, medicine use and immune activity. These changes may also alter the intestinal microbiome. Research into viral respiratory infections suggests that the relationship between the gut and lungs may operate in both directions.

What Does the Evidence Show?

The gut–lung axis is a scientifically important research area, but much of the evidence remains experimental or associative.

Current evidence	Interpretation
Gut microorganisms influence immune development and metabolism	Supported biological principle
Microbial metabolites can affect distant immune responses	Supported by experimental and growing human evidence
Altered gut microbiomes are associated with asthma, allergies and respiratory infections	Association does not prove direct causation
Selected probiotic strains may produce condition-specific benefits	Benefits depend on the exact strain, dose and patient group
Any probiotic can prevent respiratory infections	Not established
Improving digestion will cure lung disease	Not supported

Researchers have reported associations between gut-microbiome patterns and conditions including asthma, allergic disease, respiratory infections and chronic inflammatory lung disorders. However, it is often unclear whether microbial changes contribute to disease, result from the disease or reflect medicines, diet and other factors.

Probiotics Are Strain-Specific

Probiotics are live microorganisms that may provide a health benefit when given in an appropriate amount. Their effects cannot be generalised across every organism or product.

The World Gastroenterology Organisation states that probiotic benefits should be linked to the specific strain or strain combination and the dose supported by clinical evidence. Evidence for one strain cannot automatically be applied to another product labelled “probiotic.”

When evaluating a probiotic product, important details include:

• Complete strain identification
• Number of viable organisms
• Dose supported by research
• Approved indication
• Storage requirements
• Expiry information
• Evidence for the specific patient group

A probiotic used for antibiotic-associated diarrhoea, for example, should not automatically be promoted for respiratory immunity.

The Role of Alflora Sachet

Alflora Sachet from Ikon Remedies contains racecadotril 10 mg, lactic acid bacillus 100 million and lyophilised Saccharomyces boulardii 2.5 billion per 1.5 g sachet. It is positioned as an antisecretory and probiotic combination for acute, infectious and antibiotic-associated diarrhoea, particularly in paediatric care.

The probiotic components are intended to help restore intestinal microbial balance when it has been disturbed by diarrhoeal illness or antibiotic use. Racecadotril reduces excessive intestinal secretion.

Alflora Sachet should not be described as a direct treatment for respiratory immunity, asthma, allergy, cough or viral respiratory infections. Its relevant role in a gut–lung discussion is the clinical management of specified gastrointestinal conditions and support for disturbed gut flora under medical supervision.

Because the product includes an antidiarrhoeal medicine as well as probiotic organisms, it should not be treated as a general daily wellness supplement. The patient’s age, hydration status, symptoms and cause of diarrhoea should be assessed by a healthcare professional.

People who are severely ill or immunocompromised should seek professional advice before using products containing live microorganisms.

Reflux: A Different Gut–Lung Connection

The gut–lung relationship also includes mechanical and neurological pathways, not only the microbiome.

In gastro-oesophageal reflux disease, stomach contents move back into the oesophagus. Reflux may contribute to:

• Chronic cough
• Throat irritation
• Hoarseness
• Frequent throat clearing
• Sour taste
• Heartburn
• Symptoms after meals or while lying down

Possible extra-oesophageal manifestations of reflux include chronic cough and laryngeal symptoms. However, these symptoms may also result from asthma, allergy, infection, smoking, medicines or other conditions. Reflux should not be assumed to be the cause without appropriate assessment.

Guidelines advise evaluating other common causes of chronic cough. Acid-suppressive treatment alone may not help patients who have a cough without typical reflux symptoms or objective evidence supporting reflux.

Where Rabepraz-DSR Capsules May Fit

Rabepraz-DSR Capsules from Ikon Remedies contain rabeprazole sodium 20 mg and sustained-release domperidone 30 mg. The formulation is used for gastro-oesophageal reflux disease, reflux oesophagitis and related gastrointestinal symptoms under medical guidance.

Rabeprazole is a proton-pump inhibitor that reduces stomach-acid production. Domperidone is a prokinetic medicine that supports upper gastrointestinal movement.

Rabepraz-DSR may be considered when a clinician diagnoses an appropriate reflux-related condition. It is not a probiotic, does not restore the gut microbiome and should not be presented as a direct respiratory-immunity treatment.

It should also not be recommended for every persistent cough. The complete formulation requires prescription-based use, consideration of other medicines and assessment of the patient’s gastrointestinal and general medical history.

Supporting Gut and Respiratory Health

General measures that may support gastrointestinal and respiratory health include:

• Eating a varied, fibre-containing diet when medically appropriate
• Drinking adequate fluids
• Using antibiotics only when prescribed
• Avoiding smoking and vaping
• Maintaining regular physical activity
• Getting sufficient sleep
• Managing reflux-triggering foods individually
• Avoiding large meals close to bedtime
• Maintaining a healthy body weight
• Following prescribed treatment for asthma, allergy or reflux

These habits may support health but cannot guarantee protection against respiratory infections.

When to Seek Medical Advice

Consult a healthcare professional for persistent diarrhoea, dehydration, blood in the stool, repeated vomiting, severe abdominal pain or symptoms in an infant.

Respiratory assessment is needed for:

• Cough lasting several weeks
• Difficulty breathing
• Wheezing
• Chest pain
• Coughing up blood
• Unexplained weight loss
• Persistent fever
• Night-time cough that repeatedly disturbs sleep
• Hoarseness or swallowing difficulty
• Symptoms that do not improve with prescribed reflux treatment

Conclusion

The gut–lung axis demonstrates that gastrointestinal and respiratory health are connected through microbial, immune, metabolic and reflux-related pathways. However, this field should not be simplified into claims that all lung disease begins in the gut.

Alflora Sachet has a defined role in selected diarrhoeal conditions and restoration of disturbed gut flora. Rabepraz-DSR Capsules have a separate role in clinically diagnosed reflux and acid-related gastrointestinal conditions that may sometimes contribute to cough or throat symptoms.

Both products should be positioned according to their approved indications—not as general treatments for respiratory immunity.